HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NU6102

structure in first source

Also Known As:

O(6)-cyclohexylmethoxy-2-(4'-sulfamoylanilino)purine

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - NU6102: 2

Experts

1.	Bentley, Johanne: 1 article (09/2011)
2.	Cheng, Yuzhu: 1 article (09/2011)
3.	Curtin, Nicola J: 1 article (09/2011)
4.	Golding, Bernard T: 1 article (09/2011)
5.	Griffin, Roger J: 1 article (09/2011)
6.	Hardcastle, Ian R: 1 article (09/2011)
7.	Newell, David R: 1 article (09/2011)
8.	Roche, Celine: 1 article (09/2011)
9.	Thomas, Huw D: 1 article (09/2011)
10.	Wang, Lan-Zhen: 1 article (09/2011)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2011 - "NU6102 and its prodrug NU6301 have pharmacological properties consistent with CDK2 inhibition, and represent useful tool molecules for the evaluation of CDK2 as a target in cancer." 09/01/2011 - "To facilitate the evaluation of CDK2 (cyclin-dependent kinase 2) as a cancer target, the in vitro and in vivo properties of NU6102 (O⁶-cyclohexylmethyl-2-(4'-sulphamoylanilino)purine) and a water soluble prodrug (NU6301) were investigated. "
2.	Breast Neoplasms (Breast Cancer) 01/19/2010 - "The cellular effects of CDK2/1 siRNA knockdown and purine-based CDK2/1 inhibitors, NU2058 and NU6102, were measured in anti-estrogen-sensitive and resistant breast cancer cell lines. "

Related Drugs and Biologics

1.	Cyclin-Dependent Kinase 2
2.	Small Interfering RNA (siRNA)
3.	Prodrugs
4.	Estrogens (Estrogen)
5.	NU2058
6.	purine